IP Verse

Buprenorphine Dosing Regimens - EP3215223

The patent EP3215223 was granted to Indivior UK on Jul 1, 2020. The application was originally filed on Nov 6, 2015 under application number EP15828368A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3215223

INDIVIOR UK
Application Number
EP15828368A
Filing Date
Nov 6, 2015
Status
Granted And Under Opposition
May 29, 2020
Grant Date
Jul 1, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ELKINGTON AND FIFEMar 30, 2021ELKINGTON AND FIFEWITHDRAWN

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO0115699
INTERNATIONAL-SEARCH-REPORTWO2011154724
INTERNATIONAL-SEARCH-REPORTWO2015136253
OPPOSITIONWO0115699
OPPOSITIONWO2011154724
OPPOSITIONWO2014016428
OPPOSITIONWO2015136253

Non-Patent Literature (NPL) Citations (6) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- John H. Collett, Soraya Dhillon, "DOSAGE REGIMENS", John H. Collett, Soraya Dhillon, Michael E. Aulton, Kevin M.G. Taylor, Aulton's Pharmaceutics: The Design and Manufacture of Medicines, Elsevier Ltd.,, (20130000), pages 2pp, 355 - 366, XP055794776
OPPOSITION- Nasser Azmi F; Heidbreder Christian; Gomeni Roberto; Fudala Paul J; Zheng Bo; Greenwald Mark K, "A Population Pharmacokinetic and Pharmacodynamic Modelling Approach to Support the Clinical Development of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Dependence", Clinical Pharmacokinetics, (20140712), vol. 53, no. 9, pages 813 - 824, XP009189013
OPPOSITION- S.E. ROBINSON, "Buprenorphine: An Analgesic with an Expanding Role in the Treatment of Opioid Addiction", CNS Drug Reviews, (20020000), vol. 8, no. 4, pages 377 - 390, XP055523198
OPPOSITION- Greenwald; Johanson M; Bueller C E; Chang J; Moody Y; Kilbourn D E; Koeppe M; Zubieta R; J K, "Buprenorphine Duration of Action: Mu-opioid Receptor Availability and Pharmacokinetic and Behavioral Indices", Biological Psychiatry, (20060000), vol. 61, pages 101 - 110, XP005798784
OPPOSITION- Bai-Fang X Sobel; Sigmon Stacey C; Walsh Sharon L; Johnson Rolley E; Liebson Ira A; Nuwayser Elie S; Kerrigan James H; Bigelow George E, "Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification", Drug and Alcohol Dependence, (20040000), vol. 73, no. 1, pages 11 - 22, XP055012972
OPPOSITION- S.C. SIGMON et al., "An injection depot formulation of buprenorphine: extended bio-delivery and effects", Addiction, (20060000), vol. 101, no. 3, pages 420 - 432, XP002501481

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents